George W. Cole

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

Jennifer R. Brown, Peter Hillmen, Stephen J. O’Brien et al. · Leukemia · 2017 · 234 citations · Full text

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

Paul M. Barr, Jennifer Brown, Peter Hillmen et al. · Blood · 2017 · 140 citations · Full text

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study

Margaret A. Tempero, Do‐Youn Oh, Josep Tabernero et al. · Annals of Oncology · 2021 · 108 citations · Full text

Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)–mediated signaling pathway

Dao Nguyen, G.Aaron Chen, Rishindra M. Reddy et al. · Journal of Thoracic and Cardiovascular Surgery · 2004 · 55 citations · Full text

Tumor Biology, Pharmacologic Inhibition, Lung Inflammation +12

Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation

M. Firdos Ziauddin, Wen-Shuz Yeow, Justin B. Maxhimer et al. · Neoplasia · 2006 · 49 citations · Full text